Biventricular cardiomyopathy improvement by shifting therapy from agalsidase alfa to agalsidase beta in Anderson‐Fabry Disease
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Treatment of Fabry disease has improved since the introduction of enzyme replacement therapy (ERT). Two preparations of the recom‐ binant enzyme α‐galactosidase A are available: agalsidase alfa and agalsidase beta. We aim to report on a disease improvement after switching therapy from agalsidase alfa to agalsidase beta in a patient with Fabry cardiomyopathy. We present a case of a 60‐year‐old male with chronic renal failure and hypothyroidism, diagnosed with Fabry disease in 2010. We investigated clinical changes in this pa‐ tient during the 12‐months follow‐up. At the time of diagnosis, transthoracic echocardiogram (TTE) and cardiac magnetic resonance (CMR) showed widespread transmural inferolateral late enhancement (LE), poor ejection fraction and severe left ventricular hypertrophy. Despite of initiation of ERT with agalsidase alfa, clinical status of the patient did not improve. A shift to agalsidase beta was made, what resulted in marked betterment. Effectiveness of ERT on Fabry cardiomyopathy primarily depends on the stage of disease at baseline, since ERT may provide limited benefits in patients with evidence of fibrosis in CMR. Switch from agalsidase alfa to agalsidase beta may be needed in some patients, who do not improve on the first‐line therapy. JRCD 2018; 3 (6): 209–212.
Authors and Affiliations
Walter Serra, Guido Pastorini
Keywords
Related Articles
- EP ID EP286565
- DOI 10.20418/jrcd.vol3no6.315
- Views 80
- Downloads 0
Arrhythmias in adult patients after total correction of tetralogy of Fallot (RCD code: V-2B.0)
Improvement of the long‑term survival of patients with Tetralogy of Fallot has been observed in the last few years. Among the late complication arrhythmias are detected most frequently. The aim of this study was to estim...
Hypertrophic cardiomyopathy – symptomatic atrial fibrillation in a patient at high risk of sudden cardiac death
We present the case of a young patient with significant left ventricular hypertrophy as a common representation of the hypertrophic cardiomyopathy (HCM) phenotype. The clinical presentation and diagnostic route of the di...
Heart broken by a mosquito; an unusual case of Takotsubo cardiomyopathy
Pakistan has recently witnessed an epidemic of dengue infection and thereafter, certain various presentations of patients with dengue infection have been reported. The cardiac manifestation of dengue infection is primari...
Improving education quality in the field of rare diseases following European Union recommendations
Dear Friends and Readers, This is always a pleasure to introduce the new issue of our Journal. This time we start from the article that confirms the importance of rare diseases problem – not only in terms of economy, but...
A 34‐year‐old man with non‐obstructive apical hypertrophic cardiomyopathy (RCD code: III‐2A.1)
Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium that is defined by the presence of regional (more frequent) or global myocardial hypertrophy, which usually results in functional cardiac impairmen...